All In Biotech

Drug Trial Radar · NCT00144261

An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets

Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Nov 1, 2003

Primary completion

Dec 1, 2006

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated. In addition, the activity of the key enzymes related to HDL metabolism were assessed. \[ Designated as safety issue: No \] 2. In order to determine the relevance of the HDL increase in decreasing cardiovascular risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate marker for cardiovascular disease in patients. \[ Designated as safety issue: No \]

Conditions

  • HIV Infections
  • Metabolism, Lipids

Interventions

  • nevirapineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change of fractional synthetic rate (FSR) of Apo A-1Time frame: after 6 weeks of treatment
  2. Percentage change of flow mediated dilatation (FMD)Time frame: after 6 and 24 weeks of treatment

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • 1100.1426.01 Academic Medical Centre

    Amsterdam, Netherlands

  • 1100.1426.02 Onze Lieve Vrouwe Gasthuis

    Amsterdam, Netherlands

  • 1100.1426.44001 Boehringer Ingelheim Investigational Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.